Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (291-300 of 520) with videos related to

Pageof 52
Sort By:
Circulation|March 21, 2007
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery diseaseMarc S Sabatine, David A Morrow, Kathleen A Jablonski, et al.
European Heart Journal|April 17, 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeMichael R MacDonald, Mark C Petrie, Fumi Varyani, et al.
American Heart Journal|April 29, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
Kidney International|July 16, 2017
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies ConferenceColin Baigent, William G Herrington, Josef Coresh, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
European Journal of Heart Failure|November 1, 2019
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trialSergio H R Ramalho, Brian L Claggett, Nancy K Sweitzer, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
European Heart Journal|May 11, 2023
Rapid, accurate publication and dissemination of clinical trial results: benefits and challengesFaiez Zannad, Filippo Crea, John Keaney, et al.
Pageof 52

Showing results (291-300 of 520) with videos related to

Sort By:
Pageof 52
Circulation|March 21, 2007
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery diseaseMarc S Sabatine, David A Morrow, Kathleen A Jablonski, et al.
European Heart Journal|April 17, 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeMichael R MacDonald, Mark C Petrie, Fumi Varyani, et al.
American Heart Journal|April 29, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
Kidney International|July 16, 2017
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies ConferenceColin Baigent, William G Herrington, Josef Coresh, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
European Journal of Heart Failure|November 1, 2019
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trialSergio H R Ramalho, Brian L Claggett, Nancy K Sweitzer, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
European Heart Journal|May 11, 2023
Rapid, accurate publication and dissemination of clinical trial results: benefits and challengesFaiez Zannad, Filippo Crea, John Keaney, et al.
Pageof 52